Clinical biomarkers for Lewy body diseases
Abstract Synucleinopathies are a group of neurodegenerative disorders characterized by pathologic aggregates of neural and glial α-synuclein (α-syn) in the form of Lewy bodies (LBs), Lewy neurites, and cytoplasmic inclusions in both neurons and glia. Two major classes of synucleinopathies are LB dis...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-11-01
|
| Series: | Cell & Bioscience |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13578-023-01152-x |
| _version_ | 1797556145658789888 |
|---|---|
| author | Mai M. Abdelmoaty Eugene Lu Rana Kadry Emma G. Foster Shaurav Bhattarai R. Lee Mosley Howard E. Gendelman |
| author_facet | Mai M. Abdelmoaty Eugene Lu Rana Kadry Emma G. Foster Shaurav Bhattarai R. Lee Mosley Howard E. Gendelman |
| author_sort | Mai M. Abdelmoaty |
| collection | DOAJ |
| description | Abstract Synucleinopathies are a group of neurodegenerative disorders characterized by pathologic aggregates of neural and glial α-synuclein (α-syn) in the form of Lewy bodies (LBs), Lewy neurites, and cytoplasmic inclusions in both neurons and glia. Two major classes of synucleinopathies are LB disease and multiple system atrophy. LB diseases include Parkinson’s disease (PD), PD with dementia, and dementia with LBs. All are increasing in prevalence. Effective diagnostics, disease-modifying therapies, and therapeutic monitoring are urgently needed. Diagnostics capable of differentiating LB diseases are based on signs and symptoms which might overlap. To date, no specific diagnostic test exists despite disease-specific pathologies. Diagnostics are aided by brain imaging and cerebrospinal fluid evaluations, but more accessible biomarkers remain in need. Mechanisms of α-syn evolution to pathologic oligomers and insoluble fibrils can provide one of a spectrum of biomarkers to link complex neural pathways to effective therapies. With these in mind, we review promising biomarkers linked to effective disease-modifying interventions. |
| first_indexed | 2024-03-10T16:57:40Z |
| format | Article |
| id | doaj.art-2c505cc77c0f419ab35ba80333b7b3fd |
| institution | Directory Open Access Journal |
| issn | 2045-3701 |
| language | English |
| last_indexed | 2024-03-10T16:57:40Z |
| publishDate | 2023-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell & Bioscience |
| spelling | doaj.art-2c505cc77c0f419ab35ba80333b7b3fd2023-11-20T11:03:58ZengBMCCell & Bioscience2045-37012023-11-0113112310.1186/s13578-023-01152-xClinical biomarkers for Lewy body diseasesMai M. Abdelmoaty0Eugene Lu1Rana Kadry2Emma G. Foster3Shaurav Bhattarai4R. Lee Mosley5Howard E. Gendelman6Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterDepartment of Cellular and Integrative Physiology, University of Nebraska Medical CenterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical CenterAbstract Synucleinopathies are a group of neurodegenerative disorders characterized by pathologic aggregates of neural and glial α-synuclein (α-syn) in the form of Lewy bodies (LBs), Lewy neurites, and cytoplasmic inclusions in both neurons and glia. Two major classes of synucleinopathies are LB disease and multiple system atrophy. LB diseases include Parkinson’s disease (PD), PD with dementia, and dementia with LBs. All are increasing in prevalence. Effective diagnostics, disease-modifying therapies, and therapeutic monitoring are urgently needed. Diagnostics capable of differentiating LB diseases are based on signs and symptoms which might overlap. To date, no specific diagnostic test exists despite disease-specific pathologies. Diagnostics are aided by brain imaging and cerebrospinal fluid evaluations, but more accessible biomarkers remain in need. Mechanisms of α-syn evolution to pathologic oligomers and insoluble fibrils can provide one of a spectrum of biomarkers to link complex neural pathways to effective therapies. With these in mind, we review promising biomarkers linked to effective disease-modifying interventions.https://doi.org/10.1186/s13578-023-01152-xSynucleinopathiesParkinson’s diseaseParkinson’s disease with dementiaDementia with Lewy bodiesα-synucleinBiomarkers |
| spellingShingle | Mai M. Abdelmoaty Eugene Lu Rana Kadry Emma G. Foster Shaurav Bhattarai R. Lee Mosley Howard E. Gendelman Clinical biomarkers for Lewy body diseases Cell & Bioscience Synucleinopathies Parkinson’s disease Parkinson’s disease with dementia Dementia with Lewy bodies α-synuclein Biomarkers |
| title | Clinical biomarkers for Lewy body diseases |
| title_full | Clinical biomarkers for Lewy body diseases |
| title_fullStr | Clinical biomarkers for Lewy body diseases |
| title_full_unstemmed | Clinical biomarkers for Lewy body diseases |
| title_short | Clinical biomarkers for Lewy body diseases |
| title_sort | clinical biomarkers for lewy body diseases |
| topic | Synucleinopathies Parkinson’s disease Parkinson’s disease with dementia Dementia with Lewy bodies α-synuclein Biomarkers |
| url | https://doi.org/10.1186/s13578-023-01152-x |
| work_keys_str_mv | AT maimabdelmoaty clinicalbiomarkersforlewybodydiseases AT eugenelu clinicalbiomarkersforlewybodydiseases AT ranakadry clinicalbiomarkersforlewybodydiseases AT emmagfoster clinicalbiomarkersforlewybodydiseases AT shauravbhattarai clinicalbiomarkersforlewybodydiseases AT rleemosley clinicalbiomarkersforlewybodydiseases AT howardegendelman clinicalbiomarkersforlewybodydiseases |